XML 51 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity
The following table presents certain information related to the activity of the Company's stock option grants:
Number of Stock OptionsWeighted Average Exercise PricesWeighted Average Remaining Contractual Term (years)
Aggregate Intrinsic Value (2)
Outstanding as of December 31, 2024
1,130,035 $4.12 7.21 $10,202,000 
Granted
— — — — 
  Less: Forfeited— — — — 
  Less: Expired— — — — 
Less: Exercised
100,141 2.96 — — 
Outstanding as of March 31, 2025
1,029,894 $4.24 6.96 $7,825,000 
Vested as of March 31, 2025(1)
1,276,019 $4.48 6.47 $5,525,000 
Exercisable as of March 31, 2025
740,627 $4.48 6.47 $5,525,000 
(1) The vested shares are calculated based on all vested shares at March 31, 2025, inclusive of those that have since expired. The weighted average exercise prices, weighted-average remaining contractual term and aggregate intrinsic value is calculated based on only vested shares that are outstanding and exercisable at March 31, 2025.
(2) Presented in ones.
Schedule of Nonvested Share Activity
The following table presents certain information related to the activity of the Company's non-vested restricted common stock grants:
Number of Restricted SharesWeighted Average Grant Date Fair Value
Outstanding as of December 31, 2024
606,411 $6.23 
Granted
33,832 12.01 
Less: Forfeited1,009 11.59 
Less: Vested 36,449 6.01 
Outstanding as of March 31, 2025
602,785 $6.56 
Share-based Payment Arrangement, Activity
The following table presents the Company's total stock-based compensation expense:
Three Months Ended March 31,
20252024
Employee stock-based compensation expense
     Pre-tax $598 $369 
     Post-tax (1)
472 292 
Director stock-based compensation expense
     Pre-tax 135 59 
     Post-tax (1)
107 47 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions The following weighted-average assumptions were used to value the stock options granted:
20252024
Expected annual dividend yield—  %—  %
Expected volatility—  %86.92  %
Risk-free interest rate—  %4.37  %
Expected termN/A6 years